Casein

Identification

Name
Casein
Accession Number
DB10516
Type
Biotech
Groups
Approved
Biologic Classification
Allergenics
Allergen Extract
Description

Casein allergenic extract is used in allergenic testing.

Synonyms
  • Bovine casein
  • Calcium caseinate
  • Casein allergenic extract
  • Casein, cow milk
  • Casein, milk
  • Milk casein
  • Milk protein
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CaseinInjection, solution0.1 g/1mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution0.05 g/1mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution0.1 g/1mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
CaseinInjection, solution0.1 mg/1mLPercutaneousAlk Abello, Inc.1998-02-23Not applicableUs
CaseinInjection, solution0.05 g/1mLIntradermal; SubcutaneousNelco Laboratories, Inc.1972-08-29Not applicableUs
Food - Dairy Products, Casein, Cow MilkInjection, solution0.1 g/1mLPercutaneous; SubcutaneousJubilant Hollisterstier Llc1941-04-19Not applicableUs
Food - Dairy Products, Casein, Cow MilkInjection, solution0.1 g/1mLPercutaneousJubilant Hollisterstier Llc1941-04-19Not applicableUs
Categories
UNII
48268V50D5
CAS number
9000-71-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCasein may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCasein may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Casein.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Casein is combined with Alfacalcidol.Approved, Nutraceutical
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Casein.Approved
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Casein.Investigational
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
BenzthiazideBenzthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CeftriaxoneThe risk or severity of adverse effects can be increased when Casein is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CinoxacinCasein can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CymarinCasein may increase the arrhythmogenic activities of Cymarin.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Casein.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Casein.Approved
DeslanosideCasein may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCasein may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCasein may increase the arrhythmogenic activities of Digoxin.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Casein is combined with Dihydrotachysterol.Approved
Dipotassium phosphateCasein can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Casein.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Casein.Approved
DoxercalciferolThe risk or severity of adverse effects can be increased when Casein is combined with Doxercalciferol.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Casein.Approved
EnoxacinCasein can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Casein which could result in a higher serum level.Experimental
EstramustineCasein can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Casein.Approved
FleroxacinCasein can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCasein can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
GarenoxacinCasein can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCasein can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCasein can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCasein may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCasein can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
Lanatoside CCasein may increase the arrhythmogenic activities of Lanatoside C.Experimental
LevofloxacinCasein can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Casein.Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Casein.Approved
LomefloxacinCasein can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MetildigoxinCasein may increase the arrhythmogenic activities of Metildigoxin.Experimental
Nalidixic AcidCasein can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCasein can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NorfloxacinCasein can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinCasein can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCasein may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OuabainCasein may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCasein can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol.Approved, Investigational
PazufloxacinCasein can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCasein can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCasein may increase the arrhythmogenic activities of Peruvoside.Experimental
Pipemidic acidCasein can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCasein can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
ProscillaridinCasein may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCasein can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Casein.Approved, Investigational
RosoxacinCasein can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCasein can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SitafloxacinCasein can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCasein can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCasein can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Casein.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Casein.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Casein.Approved
TemafloxacinCasein can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Casein.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Casein.Approved, Investigational, Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Casein.Approved, Investigational
TrovafloxacinCasein can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910679
Wikipedia
Casein

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntradermal; Subcutaneous0.05 g/1mL
Injection, solutionIntradermal; Subcutaneous0.1 g/1mL
Injection, solutionPercutaneous0.1 mg/1mL
Injection, solutionPercutaneous0.1 g/1mL
Injection, solutionPercutaneous; Subcutaneous0.1 g/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on August 02, 2018 06:19